Psilocybin for Depression: Compass Pathways Inches Toward Historic FDA Approval

Psilocybin — the active compound in "magic mushrooms" — may become the first classic psychedelic approved by the FDA. Compass Pathways has begun a rolling NDA submission backed by positive Phase 3 data across three large trials, and the agency has awarded a priority review voucher that could compress timelines to just 1-2 months post-filing.

Roughly 4 million Americans live with treatment-resistant depression (TRD) — people who failed to respond to at least two adequate courses of approved antidepressants. They face higher functional impairment, greater comorbidity, and elevated suicide risk. Compass Pathways' COMP360 is directly targeting this population.

Stock Jumps 14% on Q1 Beat and Regulatory Momentum

Shares of Compass Pathways (CMPS) rose 14% on May 13 after Q1 2026 results came in well ahead of expectations. The adjusted loss per share was $0.30 versus the consensus estimate of $0.43. R&D expenses declined as the Phase 3 program neared completion. The company ended the quarter with $466 million in cash — enough to fund operations "well beyond launch and into 2028," it said.

Three Phase 3 Trials, Three Wins — FDA Takes Notice

More important than the financials was the regulatory news. The FDA granted a rolling NDA submission and review for COMP360, meaning Compass can file completed sections progressively rather than all at once, shaving months off the standard timeline. Sections are already under review. On top of that, FDA selected COMP360 for its Commissioner's National Priority Voucher (CNPV) program — a designation that compresses the post-filing review period from the standard 12 months down to just 1-2 months.

"COMP360 represents a fundamentally different approach for patients with treatment-resistant depression, unlike any other treatment approved today. We are ready to deliver for those who have waited far too long for better options."

Kabir Nath, CEO of Compass Pathways

The regulatory acceleration rests on an unusually clean clinical track record. COMP360 has now produced statistically significant, clinically meaningful results in three large late-stage trials enrolling over 1,000 TRD patients combined — a 3-for-3 record that is rare in psychiatry drug development.

What Psilocybin Does Differently

COMP360 is a synthetic form of psilocybin — the compound found in certain mushroom species. Its mechanism differs entirely from existing antidepressants. It acts as a serotonin 5-HT2A receptor agonist, hypothesized to induce neuroplastic changes in the brain. The key clinical promise: durable antidepressant effects from just a few treatment sessions, rather than daily chronic dosing. The Trump administration has also issued an executive order directing the DEA to fast-track rescheduling for psychedelic treatments that have completed Phase 3 trials.

Competing With J&J's Spravato — Same Market, Different Mechanism

The only current TRD approval is Johnson & Johnson's Spravato (esketamine nasal spray), cleared in 2019 and generating $1.7 billion in sales in 2025. COMP360 would be its first direct competitor. Jefferies analysts noted that COMP360's infrastructure requirements are similar to Spravato's — more than 7,000 US treatment centers already operate in the space. They project FDA approval by year-end 2026, DEA rescheduling, and a commercial launch in early 2027, with peak sales potential in the multi-billion dollar range.

Key Milestones Ahead

• Early Q3 2026: 26-week Phase 3 durability data (Part B) — needed to complete the NDA
• Q4 2026: Final NDA submission
• 1-2 months after filing: CNPV-accelerated review
• Year-end 2026 or early 2027: FDA approval decision
• Post-approval: DEA rescheduling → commercial launch